Data sheet
| Size | 100ug/vial |
| Storage | At -20C for one year. After reconstitution, at 4C for one month. |
| Application | Cross ReactivityHuman, mouse, rat. |
| Form | lyophilized |
| Ig type | mouse IgG1 |
| Immunogen/Antigen | slightly modified β-cytoplasmic actin N-terminal peptide, |
| Reconstitution | 1.2% sodium acetate or neutral PBS. If 1ml of PBS is used, |
| Clone | AC-15 |
| Cross Reactivity | Human, mouse, rat. |
More info
Background
The primary site of action of cytochalasin B on cell motility processes is beta-actin. Habets et al. (1992) generated hybrids that harbor only specific regions of human chromosome 7 and assigned the ACTB locus to 7p15-p12. ACTB and the other assigned beta-actin-related sequences are dispersed over at least four different chromosomes including one locus assigned to the X chromosome. A mutation of beta-actin that alters depolymerization dynamics is associated with autosomal dominant developmental malformations, deafness, and dystonia.
The primary site of action of cytochalasin B on cell motility processes is beta-actin. Habets et al. (1992) generated hybrids that harbor only specific regions of human chromosome 7 and assigned the ACTB locus to 7p15-p12. ACTB and the other assigned beta-actin-related sequences are dispersed over at least four different chromosomes including one locus assigned to the X chromosome. A mutation of beta-actin that alters depolymerization dynamics is associated with autosomal dominant developmental malformations, deafness, and dystonia.